These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25499431)

  • 1. Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein.
    McEneny-King A; Edginton AN; Rao PP
    Bioorg Med Chem Lett; 2015 Jan; 25(2):297-301. PubMed ID: 25499431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease.
    Coin A; Pamio MV; Alexopoulos C; Granziera S; Groppa F; de Rosa G; Girardi A; Sergi G; Manzato E; Padrini R
    Eur J Clin Pharmacol; 2016 Jun; 72(6):711-7. PubMed ID: 26952092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
    Magliulo L; Dahl ML; Lombardi G; Fallarini S; Villa LM; Biolcati A; Scordo MG
    Eur J Clin Pharmacol; 2011 Jan; 67(1):47-54. PubMed ID: 20931330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
    Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
    Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo.
    Li M; de Graaf IA; van de Steeg E; de Jager MH; Groothuis GM
    Toxicol In Vitro; 2017 Apr; 40():26-33. PubMed ID: 27939799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
    Wang E; Lew K; Barecki M; Casciano CN; Clement RP; Johnson WW
    Chem Res Toxicol; 2001 Dec; 14(12):1596-603. PubMed ID: 11743742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4.
    Achira M; Suzuki H; Ito K; Sugiyama Y
    AAPS PharmSci; 1999; 1(4):E18. PubMed ID: 11741214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
    Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
    Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor.
    Sahi J; Milad MA; Zheng X; Rose KA; Wang H; Stilgenbauer L; Gilbert D; Jolley S; Stern RH; LeCluyse EL
    J Pharmacol Exp Ther; 2003 Sep; 306(3):1027-34. PubMed ID: 12766253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive assessment of Cucurbitacin E related hepatotoxicity and drug-drug interactions involving CYP3A and P-glycoprotein.
    Lu J; Zhang Y; Sun M; Liu M; Wang X
    Phytomedicine; 2017 Mar; 26():1-10. PubMed ID: 28257659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates.
    Yalkinoglu Ö; Becker A; Krebs-Brown A; Vetter C; Lüpfert C; Perrin D; Heuer J; Biedert H; Hirt S; Bytyqi A; Bachmann A; Strotmann R
    Invest New Drugs; 2023 Aug; 41(4):596-605. PubMed ID: 37415001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
    Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
    Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: herb-drug interactions mediated via P-gp.
    Li X; Hu J; Wang B; Sheng L; Liu Z; Yang S; Li Y
    Toxicol Appl Pharmacol; 2014 Mar; 275(2):163-75. PubMed ID: 24380838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of 2,4-diamino-5-fluoropyrimidine derivatives as protein kinase C theta inhibitors with mitigated time-dependent drug-drug interactions and P-gp liability.
    Kunikawa S; Tanaka A; Mukoyoshi K; Nagashima S; Tominaga H; Chida N; Tasaki M; Shirai F
    Bioorg Med Chem; 2015 Jul; 23(13):3269-77. PubMed ID: 25982074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data.
    Benet LZ; Cummins CL; Wu CY
    Curr Drug Metab; 2003 Oct; 4(5):393-8. PubMed ID: 14529371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
    Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
    Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.
    Brandes LJ; Queen GM; LaBella FS
    Cancer Chemother Pharmacol; 2000; 45(4):298-304. PubMed ID: 10755318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome p450 inhibitory properties of common efflux transporter inhibitors.
    Englund G; Lundquist P; Skogastierna C; Johansson J; Hoogstraate J; Afzelius L; Andersson TB; Projean D
    Drug Metab Dispos; 2014 Mar; 42(3):441-7. PubMed ID: 24396142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
    Patel J; Mitra AK
    Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.